Regeneus Ltd. (CMB) AI Stock Analysis

• Market Cap: AU$11.25M
• Dividend Yield: N/A
• Average Volume (3M): 3.93K
• Price to Earnings (P/E): ―
• Beta (1Y): -8.03
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 22,968,280
• 10 Day Avg. Volume: 7,693
• 30 Day Avg. Volume: 3,926
• PEG Ratio: 0.02
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 5.73
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$0.52 ▲(10.64% Upside)
• Action: Reiterated Date: 01/24/26
• Date: Action: Reiterated 01/24/26

The score is held back primarily by weak financial performance—large ongoing losses and significant cash burn that increase funding risk—despite improving revenue off a low base. Technicals are supportive of a bullish trend but appear overextended, and valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

High gross margin

A ~69% gross margin signals strong unit economics for Regeneus’ cell-based products and therapies. If revenue scales or licensing deals materialize, this margin provides structural leverage to move toward profitability, making future revenue growth more accretive to operating results.

Recent revenue rebound

A sharp revenue rebound indicates improving commercial traction or milestone-related income versus a depressed prior base. Sustained top-line recovery over quarters could validate the business model, support partner interest, and reduce execution risk as operations scale beyond minimal levels.

Moderate leverage

Relatively low debt reduces fixed financial obligations and interest burden, preserving operational flexibility. Moderate leverage gives the company runway to pursue R&D and partnership options without immediate pressure from creditors, a durable advantage while seeking non-debt funding.

Negative Factors

Large operating cash burn

Sustained negative operating and free cash flow of ~A$5.2m in FY2025 erodes reserves and forces reliance on external financing or spending cuts. Persistent cash burn materially increases funding and dilution risk, constraining the company’s ability to invest and execute long-term programs without capital raises.

Repeat net losses

Meaningful recurring net losses with deeply negative operating margins indicate the current cost base far exceeds revenue run-rate. Unless revenue growth accelerates sustainably, profitability remains distant, undermining ROI for investors and limiting internal capacity to fund development or commercialization.

Shrinking equity and prior negative equity

A history of declining and previously negative equity signals balance-sheet stress and past solvency pressure. This pattern increases the probability of future equity issuance to fund operations, diluting shareholders and signaling structural financing vulnerability if operating losses continue.

Regeneus Ltd. Business Overview & Revenue Model

Company Description

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

How the Company Makes Money

Regeneus Ltd. Financial Statement Overview

Summary

Despite a sharp FY2025 revenue rebound and healthy gross margin (~69%), results remain dominated by large losses (FY2025 net loss ~A$3.84m) and accelerating cash burn (FY2025 operating/FCF about -A$5.25m). Leverage is moderate, but shrinking equity and prior negative equity indicate ongoing funding/dilution risk.

Income Statement

Revenue rebounded sharply in FY2025 (A$0.67m, up ~65% YoY) after an extremely low FY2024 base, and gross margin is healthy (~69%). However, profitability remains very weak: FY2025 net loss was ~A$3.84m with deeply negative operating margins, indicating the cost base is far larger than the current revenue run-rate. Results have been volatile over time (profit in FY2021, losses in most other years), which reduces earnings quality and visibility.

Balance Sheet

Leverage is currently moderate, with debt-to-equity at ~0.26 in FY2025 (debt ~A$0.48m vs equity ~A$1.84m), suggesting the company is not heavily debt-funded at present. That said, equity has declined materially from FY2024, and returns on equity are strongly negative in FY2025 due to ongoing losses. The history also shows prior balance sheet stress (negative equity in FY2023), highlighting dilution/solvency risk if losses persist.

Cash Flow

Cash generation is a key weak spot: FY2025 operating cash flow was ~-A$5.24m and free cash flow ~-A$5.25m, implying significant cash burn. While free cash flow tracked net income closely (free cash flow roughly in line with the reported loss), the magnitude of outflows worsened sharply versus FY2024, raising near-term funding risk and reducing financial flexibility unless new capital is raised or spending is reduced.

Breakdown	Jun 2024	Jun 2023	Jun 2023	Jun 2021	Jun 2021
Income Statement
Total Revenue	670.06K	719.00	0.00	0.00	7.07M
Gross Profit	464.32K	719.00	-6.42K	-24.96K	0.00
EBITDA	-3.80M	-1.98M	-3.09M	-4.74M	2.37M
Net Income	-3.84M	-2.26M	-3.38M	-4.31M	2.76M
Balance Sheet
Total Assets	3.30M	5.65M	2.48M	2.55M	8.51M
Cash, Cash Equivalents and Short-Term Investments	166.41K	2.86M	302.79K	164.40K	3.79M
Total Debt	482.71K	468.32K	1.95M	1.01M	13.84K
Total Liabilities	1.46M	2.87M	4.43M	1.48M	4.36M
Stockholders Equity	1.84M	2.78M	-1.81M	1.07M	4.15M
Cash Flow
Free Cash Flow	-5.25M	-155.86K	-659.66K	-3.60M	2.41M
Operating Cash Flow	-5.24M	-155.86K	-660.46K	-3.59M	2.42M
Investing Cash Flow	-333.48K	-416.13K	-48.13K	-8.47K	-7.78K
Financing Cash Flow	2.88M	3.13M	916.27K	-97.83K	400.00K

Regeneus Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CMB	48 Neutral	AU$11.25M	-2.68	-166.70%	―	―	―
IXC	48 Neutral	AU$9.39M	-11.26	-8.72%	―	―	71.10%
BGT	46 Neutral	AU$10.07M	-3.47	―	―	―	―
HXL	40 Underperform	AU$2.17M	-9.29	-28.49%	―	―	46.43%
1AD	37 Underperform	AU$10.20M	-2.38	-628.72%	―	―	31.87%

Regeneus Ltd. Corporate Events

Cambium Bio Narrows Half-Year Loss and Turns NTAs Positive as Revenue Grows

Cambium Bio Limited reported a 9% rise in revenue from ordinary activities to $327,000 for the half-year ended 31 December 2025, alongside other income of $584,000, reflecting modest top-line growth as it advances its regenerative medicine programs. The company still recorded a net loss after tax of $1.46 million, though this loss narrowed by 16% year on year, and its net tangible assets per security improved from negative $0.06 to positive $0.01, indicating a stronger balance sheet but no near-term dividends for shareholders.

These results highlight Cambium Bio’s ongoing investment in clinical development of its ophthalmology and tissue repair candidates while gradually improving its financial position. The shift to a positive net tangible asset base may bolster investor confidence and supports its positioning as a clinical-stage player aiming to commercialise novel treatments for dry eye disease and musculoskeletal conditions.

The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

Cambium Bio Plans Significant Share Placement to Raise Equity

Cambium Bio Limited has notified the ASX of its intention to issue up to 21,276,596 new fully paid ordinary shares under a proposed placement or similar capital-raising structure. The new securities, expected to be issued in mid-June 2026, signal a significant equity raising that may dilute existing shareholders but is likely aimed at strengthening the company’s balance sheet and funding ongoing projects, with potential implications for its market positioning and future growth capacity.

The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.57 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

Cambium Bio Calls Vote on Share Placement to Boost Major Holder’s Control

Cambium Bio Limited has called an online general meeting for 16 March 2026, asking shareholders to approve the issue of 4,363,637 placement shares to Zheng Yang Biomedical Technology Co., Ltd. The proposed placement would lift the combined relevant interest and voting power of major shareholder Sebastian Tseng and ZYBT from 30.1% to as much as 41.3%, consolidating control in their hands.

An independent expert, Hall Chadwick, has concluded that the control transaction is fair and reasonable to non-associated shareholders, a key hurdle for the deal under Australian corporate law. Voting exclusions will apply to Tseng, ZYBT and their associates, with instructions set out for proxies and fiduciary holders, underscoring governance requirements as the company seeks shareholder approval for the capital raising and change in control dynamics.

The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.57 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

Cambium Bio Secures Funding and Advances Toward Phase 3 Trials for Elate Ocular

Cambium Bio has strengthened its funding position ahead of pivotal Phase 3 trials of its dry eye candidate Elate Ocular®, receiving a A$0.6 million R&D Tax Incentive refund under an approved Advance Overseas Finding that provides a 43.5% cash rebate on eligible R&D spending through FY2027. The company also secured a A$2.4 million strategic placement at a 20% premium from major shareholder Zheng Yang Biomedical Technology, which, subject to shareholder approval in March, will help fund the initiation of patient dosing in its CAMOMILE-2 and CAMOMILE-3 Phase 3 studies, while it advances manufacturing, clinical preparations and licensing discussions for Elate Ocular® in Europe and the Middle East to support its future commercialisation and broaden its international footprint.

The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

Cambium Bio Plans Share Placement to Raise Fresh Capital

Cambium Bio Limited has announced a proposed placement of up to 4,363,637 new fully paid ordinary shares on the ASX, with an expected issue date of 17 March 2026. The capital raising signals an effort to strengthen the company’s balance sheet and support ongoing activities, a common approach among smaller biotech issuers seeking funds for development pipelines and operational needs, and will modestly dilute existing shareholders while potentially improving the company’s financial flexibility and market positioning.

The most recent analyst rating on (AU:CMB) stock is a Sell with a A$0.44 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.

Cambium Bio Raises A$2.4m at Premium from Major Shareholder to Fund Phase 3 Dry Eye Trials

Cambium Bio has secured a A$2.4 million strategic equity investment from major shareholder and long-term partner ZYBT via a placement of 4,363,637 new shares at A$0.55, a 20% premium to the last closing price, which will increase ZYBT’s stake from 28.1% to about 39.6%, subject to shareholder approval. The funds, alongside recent financing initiatives, will be directed to initiating patient dosing and manufacturing investigational product for pivotal Phase 3 trials of Elate Ocular® in the United States, Australia and Taiwan, strengthening Cambium Bio’s capital position and strategic alignment as it advances a late-stage program in the sizeable dry eye disease market.

The most recent analyst rating on (AU:CMB) stock is a Sell with a A$0.44 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.